KRW 12680.0
(0.08%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1856.16 Billion KRW | 14.22% |
2022 | 1625.01 Billion KRW | 2.45% |
2021 | 1586.1 Billion KRW | 1.17% |
2020 | 1567.7 Billion KRW | 23.71% |
2019 | 1267.27 Billion KRW | 7.81% |
2018 | 1175.48 Billion KRW | 4.86% |
2017 | 1121.02 Billion KRW | 28.52% |
2016 | 872.26 Billion KRW | 16.1% |
2015 | 751.28 Billion KRW | 23.2% |
2014 | 609.8 Billion KRW | 16.27% |
2013 | 524.45 Billion KRW | 10.76% |
2012 | 473.5 Billion KRW | -87.23% |
2011 | 3707.45 Billion KRW | 13.33% |
2010 | 3271.49 Billion KRW | 15.89% |
2009 | 2823.05 Billion KRW | 16.03% |
2008 | 2433.06 Billion KRW | 16.94% |
2007 | 2080.54 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1994.77 Billion KRW | 3.22% |
2024 Q1 | 1932.61 Billion KRW | 4.12% |
2023 Q2 | 1723.71 Billion KRW | 3.31% |
2023 FY | 1856.16 Billion KRW | 14.22% |
2023 Q3 | 1817.11 Billion KRW | 5.42% |
2023 Q4 | 1856.16 Billion KRW | 2.15% |
2023 Q1 | 1668.43 Billion KRW | 2.67% |
2022 Q4 | 1625.01 Billion KRW | -4.5% |
2022 Q2 | 1618.04 Billion KRW | 1.29% |
2022 FY | 1625.01 Billion KRW | 2.45% |
2022 Q1 | 1597.46 Billion KRW | 0.72% |
2022 Q3 | 1701.57 Billion KRW | 5.16% |
2021 Q3 | 1567 Billion KRW | -3.46% |
2021 Q2 | 1623.12 Billion KRW | -0.66% |
2021 Q4 | 1586.1 Billion KRW | 1.22% |
2021 FY | 1586.1 Billion KRW | 1.17% |
2021 Q1 | 1633.84 Billion KRW | 4.22% |
2020 FY | 1567.7 Billion KRW | 23.71% |
2020 Q4 | 1567.7 Billion KRW | -7.85% |
2020 Q2 | 1682.59 Billion KRW | 28.16% |
2020 Q1 | 1312.86 Billion KRW | 3.6% |
2020 Q3 | 1701.27 Billion KRW | 1.11% |
2019 Q4 | 1267.27 Billion KRW | -0.48% |
2019 FY | 1267.27 Billion KRW | 7.81% |
2019 Q1 | 1152.58 Billion KRW | -1.95% |
2019 Q2 | 1216.22 Billion KRW | 5.52% |
2019 Q3 | 1273.38 Billion KRW | 4.7% |
2018 Q2 | 1170.43 Billion KRW | 2.65% |
2018 Q1 | 1140.21 Billion KRW | 1.71% |
2018 FY | 1175.48 Billion KRW | 4.86% |
2018 Q4 | 1175.48 Billion KRW | -4.11% |
2018 Q3 | 1225.85 Billion KRW | 4.74% |
2017 Q4 | 1121.02 Billion KRW | 7.25% |
2017 Q2 | 1005.2 Billion KRW | 14.5% |
2017 Q1 | 877.92 Billion KRW | 0.65% |
2017 FY | 1121.02 Billion KRW | 28.52% |
2017 Q3 | 1045.23 Billion KRW | 3.98% |
2016 Q4 | 872.26 Billion KRW | -2.95% |
2016 Q3 | 898.8 Billion KRW | 2.45% |
2016 Q2 | 877.33 Billion KRW | 9.41% |
2016 Q1 | 801.88 Billion KRW | 6.74% |
2016 FY | 872.26 Billion KRW | 16.1% |
2015 FY | 751.28 Billion KRW | 23.2% |
2015 Q1 | 662.32 Billion KRW | 8.61% |
2015 Q2 | 733.29 Billion KRW | 10.72% |
2015 Q3 | 685.03 Billion KRW | -6.58% |
2015 Q4 | 751.28 Billion KRW | 9.67% |
2014 Q4 | 609.8 Billion KRW | 1.29% |
2014 Q3 | 602.07 Billion KRW | -1.82% |
2014 Q2 | 613.26 Billion KRW | 8.23% |
2014 Q1 | 566.63 Billion KRW | 8.04% |
2014 FY | 609.8 Billion KRW | 16.27% |
2013 FY | 524.45 Billion KRW | 10.76% |
2013 Q1 | 477.7 Billion KRW | 0.89% |
2013 Q2 | 501.34 Billion KRW | 4.95% |
2013 Q3 | 523.91 Billion KRW | 4.5% |
2013 Q4 | 524.45 Billion KRW | 0.1% |
2012 FY | 473.5 Billion KRW | -87.23% |
2012 Q3 | 465.13 Billion KRW | 5.69% |
2012 Q4 | 473.5 Billion KRW | 1.8% |
2012 Q1 | 404.85 Billion KRW | -89.08% |
2012 Q2 | 440.07 Billion KRW | 8.7% |
2011 FY | 3707.45 Billion KRW | 13.33% |
2011 Q4 | 3707.45 Billion KRW | 2.63% |
2011 Q3 | 3612.3 Billion KRW | 3.63% |
2011 Q2 | 3485.81 Billion KRW | 3.06% |
2011 Q1 | 3382.33 Billion KRW | 0.0% |
2010 Q3 | 337.01 Billion KRW | 31.17% |
2010 FY | 3271.49 Billion KRW | 15.89% |
2010 Q1 | 215.25 Billion KRW | 0.0% |
2010 Q2 | 256.91 Billion KRW | 19.36% |
2009 FY | 2823.05 Billion KRW | 16.03% |
2009 Q3 | 187.54 Billion KRW | -8.59% |
2009 Q2 | 205.16 Billion KRW | 4.97% |
2009 Q1 | 195.45 Billion KRW | 0.0% |
2008 Q2 | 180.07 Billion KRW | -1.67% |
2008 Q3 | 175.69 Billion KRW | -2.43% |
2008 FY | 2433.06 Billion KRW | 16.94% |
2008 Q1 | 183.12 Billion KRW | 0.0% |
2007 FY | 2080.54 Billion KRW | 0.0% |
2007 Q1 | 184.52 Billion KRW | 0.0% |
2007 Q2 | 229.96 Billion KRW | 24.62% |
2007 Q3 | 221.6 Billion KRW | -3.63% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ORIENT BIO Inc. | 11.89 Billion KRW | -15508.776% |
Green Cross Holdings Corporation | 1103.45 Billion KRW | -68.215% |
Pharmicell Co., Ltd. | 18.79 Billion KRW | -9776.195% |
Green Cross Corporation | 1103.45 Billion KRW | -68.215% |
GeneOne Life Science, Inc. | 39.51 Billion KRW | -4596.954% |
Celltrion, Inc. | 2791.73 Billion KRW | 33.512% |
Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 70.137% |
SK bioscience Co.,Ltd. | 148.58 Billion KRW | -1149.238% |
SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | -361.481% |
Prestige BioPharma Limited | 196.21 Billion KRW | -845.968% |